Singh Vivek Ajit, Puri Ajay
National Orthopaedic Centre of Excellence in Research & Learning (NOCERAL), Department of Orthopaedic Surgery, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia.
Tata Memorial Centre, Mumbai, Maharashtra, India.
J Orthop Surg (Hong Kong). 2020 Sep-Dec;28(3):2309499020979750. doi: 10.1177/2309499020979750.
Giant cell tumour of the bone (GCTB) has been classically treated surgically. With the advent of denosumab, there is potential to use it as a targeted therapy to downstage the tumour and control its progression. Like all new therapies, the dosage, duration, and long-term effects of treatment can only be determined over the time through numerous trials and errors. The current recommendation of use of the monoclonal antibody is 3-4 months of neoadjuvant denosumab in patients with advanced GCTB for cases who were not candidates for primary curettage initially, and prolonged use for surgically unsalvageable GCTB. The use of Denosumab in the adjuvant setting to prevent recurrence is not established.
骨巨细胞瘤（GCTB）传统上采用手术治疗。随着地诺单抗的出现，有潜力将其用作靶向治疗，以降低肿瘤分期并控制其进展。与所有新疗法一样，治疗的剂量、持续时间和长期效果只能通过大量的试验和错误在一段时间内确定。目前对于单克隆抗体的使用建议是，对于最初不适合进行初次刮除术的晚期GCTB患者，使用3 - 4个月的新辅助地诺单抗，对于手术无法挽救的GCTB患者则延长使用时间。地诺单抗在辅助治疗中预防复发的应用尚未确立。
